🇺🇸 Sucralfate Suspension in United States

13 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Asthenia — 3 reports (23.08%)
  2. Anaemia — 2 reports (15.38%)
  3. Abdominal Pain — 1 report (7.69%)
  4. Acute Kidney Injury — 1 report (7.69%)
  5. Atrial Fibrillation — 1 report (7.69%)
  6. Blood Creatinine Increased — 1 report (7.69%)
  7. Blood Lactate Dehydrogenase Increased — 1 report (7.69%)
  8. Blood Loss Anaemia — 1 report (7.69%)
  9. Burning Sensation — 1 report (7.69%)
  10. Cardio-Respiratory Arrest — 1 report (7.69%)

Source database →

Sucralfate Suspension in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is Sucralfate Suspension approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for Sucralfate Suspension in United States?

LanZhou University is the originator. The local marketing authorisation holder may differ — check the official source linked above.